- Home
- AYI vs JAZZ Comparison
AYI vs JAZZ Comparison
Compare AYI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYI | JAZZ |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.4B |
| IPO Year | 2001 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AYI | JAZZ |
|---|---|---|
| Price | $264.57 | $180.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $386.83 | $215.92 |
| AVG Volume (30 Days) | 412.4K | ★ 944.5K |
| Earning Date | 04-02-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.82 | N/A |
| Revenue | ★ $3,461,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $10.09 | $6.17 |
| Revenue Next Year | $5.39 | $7.66 |
| P/E Ratio | $69.58 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $216.81 | $95.49 |
| 52 Week High | $380.17 | $198.00 |
Technical Indicators
Market Signals| Indicator | AYI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 52.38 |
| Support Level | $264.31 | $176.67 |
| Resistance Level | $313.18 | $182.99 |
| Average True Range (ATR) | 8.13 | 4.97 |
| MACD | -0.66 | -1.09 |
| Stochastic Oscillator | 18.78 | 25.88 |
Price Performance
Historical ComparisonAbout AYI Acuity Brands Inc.
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.